Identification

Summary

Sulfur hexafluoride is a medication used in ultrasound to enhance viewing of blood vessels and the urinary tract.

Brand Names
Lumason, Sonovue
Generic Name
Sulfur hexafluoride
DrugBank Accession Number
DB11104
Background

Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 146.05
Monoisotopic: 145.962490152
Chemical Formula
F6S
Synonyms
  • hexafluoridosulfur
  • Sulfur fluoride
  • Sulfur hexafluoride
  • sulfur(6+) fluoride
  • sulfur(VI) fluoride
  • Sulphur hexafluoride

Pharmacology

Indication

Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border. Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Sulfur hexafluoride provides useful echocardiographic signal intensity for two minutes after the injection. Sulfur hexafluoride microspheres are destroyed and contrast enhancement decreases as the mechanical index increases (values of 0.8 or less are recommended). For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.

Mechanism of action

Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues.

Absorption

The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses.

Volume of distribution

In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.

Protein binding

Not Available

Metabolism

SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.

Route of elimination

The SF6 component of Lumason is eliminated via the lungs.

Half-life

The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.)

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SonovueInjection, powder, for solution8 μl/mlIntravenousBracco International B.V.2016-09-08Not applicableEU flag
SonovuePowder, for suspension8 mcL / mLIntravenous; IntravesicalBracco Imaging S.P.A.2016-09-22Not applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
LumaSonSulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg)KitIntravenous; IntravesicalBracco Diagnostics Inc2020-01-15Not applicableUS flag
LumaSonSulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg)KitIntravenous; IntravesicalBracco Suisse SA2015-01-15Not applicableUS flag
LumasonSulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg)Injection, powder, lyophilized, for suspensionIntravenous; IntravesicalBracco Diagnostics Inc2021-04-01Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as other non-metal halides. These are inorganic compounds containing 'other non-metals' and halogen.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Other non-metal halides
Sub Class
Not Available
Direct Parent
Other non-metal halides
Alternative Parents
Not Available
Substituents
Other non-metal halide
Molecular Framework
Not Available
External Descriptors
sulfur coordination entity (CHEBI:30496)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
WS7LR3I1D6
CAS number
2551-62-4
InChI Key
SFZCNBIFKDRMGX-UHFFFAOYSA-N
InChI
InChI=1S/F6S/c1-7(2,3,4,5)6
IUPAC Name
hexafluoro-λ⁶-sulfane
SMILES
FS(F)(F)(F)(F)F

References

General References
  1. FDA label [Link]
KEGG Drug
D05962
PubChem Compound
17358
PubChem Substance
347827897
ChemSpider
16425
RxNav
1599276
ChEBI
30496
ChEMBL
CHEMBL1796998
ZINC
ZINC000245224194
Wikipedia
Sulfur_hexafluoride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingDiagnosticAbdominal Injuries / Falls, Accidental / Motor Vehicle Injury / Physical Abuse1
4RecruitingDiagnosticAbdominal Trauma1
4RecruitingDiagnosticHepatic Disease1
4RecruitingDiagnosticRenal Malignant Tumor1
4RecruitingDiagnosticTrauma Abdomen1
4TerminatedDiagnosticCrohn's Disease (CD)1
4TerminatedDiagnosticLiver Biopsy1
4WithdrawnDiagnosticBone Marrow Transplant Complications / Sinusoidal Obstruction Syndrome (SOS) / Stem Cell Transplant Complications / Veno Occlusive Disease, Hepatic1
4WithdrawnDiagnosticNeonatal Post-Hemorrhagic Hydrocephalus1
3CompletedDiagnosticAtherosclerosis / Carotid Artery Plaque / Stroke, Ischemic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionIntravenous; Intravesical
KitIntravenous; Intravesical
Injection, powder, for solutionIntravenous8 μl/ml
PowderIntravenous; Parenteral8 MCG/ML
Powder, for suspensionIntravenous; Intravesical8 mcL / mL
Injection, powder, for solutionIntravenous8 microlitres/ml
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5686060No1997-11-112017-11-11US flag
US10232061No2019-03-192038-07-06US flag
US10335502No2019-07-022038-07-06US flag

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity18.44 m3·mol-1ChemAxon
Polarizability7.11 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at December 03, 2015 16:51 / Updated at November 28, 2021 11:56